Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials

Cancer

Volumn 97, Issue 11, 2003, Pages 2869-2879

  Swain, Sandra M ^a   Whaley, Fredrick S ^b   Ewer, Michael S ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Global Statistics and Programming   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast carcinoma; Cardiotoxicity; Chemotherapy; Congestive heart failure (CHF); Dexrazoxane; Doxorubicin; Nonsmall cell lung carcinoma; Radionuclide angiocardiography

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; RAZOXANE; VINCRISTINE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOXORUBICIN; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 0038521374     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11407     Document Type: Article

References (24)

1. Von Hoff D, Layard M, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-717.
2. Swain S, Whaley F, Gerber M, et al. Cardioprotection with dexrazoxane for doxorubicin -containing therapy in advanced breast cancer. J Clin Oncol. 1997;15:1318-1332.
3. Swain S, Whaley F, Gerber M, et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol. 1997;15:1333-1340.
4. Feldmann J, Jones S, Weisberg S, et al. Advanced small cell lung cancer treated with CAV (cyclophosphamide-Adriamycin® + vincristine) chemotherapy and the cardioprotective agent dexrazoxane (ADR-529, ICRF-187, Zinecard®). Proc Am Soc Clin Oncol. 1992;11:296.
5. The Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels, 9th ed. Boston: Little, Brown & Co, 1994:253-256.
6. Speyer J, Green M, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer [published erratum appears in J Clin Oncol. 1992;10:867]. J Clin Oncol. 1992;10:117-127.
7. Schwartz R, McKenzie W, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82:1109-1118.
8. Suzuki J, Yanagisawa A, Shigeyama T, et al. Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography. Angiology. 1999;50:37-45.
9. Herman E, Zhang J, Lipshultz S, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol. 1999;17:2237-2243.
10. Lipshultz S, Rifai N, Sallan S, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation. 1997;96:2641-2648.
11. Mason J, Bristow M, Billingham M, et al. Invasive and noninvasive methods of assessing Adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Report. 1978;62: 857-864.
12. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96:133-139.
13. Jain K, Casper E, Geller N, et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol. 1985;3:818-826.
14. Ryberg M, Nielsen D, Skovsgaard T, et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol. 1998;16:3502-3508.
15. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, longterm observational study of outcome in 120 patients. Ann OncoL 2002;13:699-709.
16. Kanter P, Bullard G, Ginsberg R, et al. Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. In Vivo. 1993;7:17-26.
17. Working P, Newman M, Sullivan T, et al. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes. J Pharmacol Exp Ther. 1999;289:1128-1133.
18. Valero V, Buzdar A, Theriault R, et al. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol. 1999;17:1425-1434.
19. Berry G, Billingham M, Alderman E, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol. 1998;9:711-716.
20. Myers C, McGuire W, Liss R, et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 1977;197:165-167.
21. Herman E, Ferrans V. Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1,2bis(3,5 dioxopiperazinyl-1-yl)propane (ICRF-187). Cancer Res. 1981;41:3436-3440.
22. Legha S, Wang Y, Mackay B, et al. Clinical and pharmacologic investigation of the effects of alpha-tocopherol on Adriamycin cardiotoxicity. Ann NY Acad Sci. 1982;393:411-418.
23. Myers C, Bonow R, Palmeri S, et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol. 1983;10:53-55.
24. Iliskovic N, Singal P. Lipid lowering: an important factor in preventing Adriamycin-induced heart failure. Am J Pathol. 1997;150:727-734.